Precipio Inc (PRPO)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $39.68M
Last updated: Nov 17, 2026 at 11:06 AM ET
Precipio Inc (PRPO) Earnings: Report Dates and Results
Precipio (PRPO) is expected to report earnings on Mar 29, 2027. In the quarter ended Jun 30, 2026, Precipio reported EPS of -$0.12. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Next Report
PRPO has an expected report date of Mar 29, 2027.
PRPO Earnings Call
The latest PRPO earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 24 quarters below that had an estimate, PRPO beat 8, missed 14 and matched 2. Revenue for the quarter ended Jun 30, 2026 was $7.02M, up 24.2% from $5.65M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$0.12 | N/A | N/A | N/A | N/A | -340.0% | N/A | N/A | Aug 14, 2026 | $7.02M |
| Mar 31, 2026 | -$0.81 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 19, 2026 | $6.71M |
| Sep 30, 2025 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2025 | $6.77M |
| Jun 30, 2025 | $0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 13, 2025 | $5.65M |
| Mar 31, 2025 | -$0.59 | N/A | N/A | N/A | N/A | -190.3% | N/A | N/A | May 14, 2025 | $4.93M |
| Dec 31, 2024 | -$0.24 | $0.74 | N/A | -133.03% | Miss | N/A | N/A | N/A | Mar 27, 2025 | $5.45M |
| Sep 30, 2024 | -$0.42 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 6, 2024 | $5.21M |
| Jun 30, 2024 | -$0.83 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 13, 2024 | $4.44M |
| Mar 31, 2024 | $0.65 | N/A | N/A | N/A | N/A | N/A | N/A | 0 up, 1 down | May 14, 2024 | $3.43M |
| Sep 30, 2023 | -$1.04 | -$1.40 | N/A | +25.71% | Beat | N/A | 1 | 1 up, 0 down | Nov 13, 2023 | $4.52M |
| Jun 30, 2023 | -$1.80 | -$2.00 | -$2.00 - -$2.00 | +10.00% | Beat | N/A | 1 | 0 up, 0 down | Aug 11, 2023 | $3.53M |
| Mar 31, 2023 | -$2.60 | -$2.60 | -$2.60 - -$2.60 | 0.00% | In line | N/A | 1 | 0 up, 0 down | May 12, 2023 | $2.82M |
| Dec 31, 2022 | -$0.10 | -$0.14 | -$0.14 - -$0.14 | +28.57% | Beat | N/A | 1 | 0 up, 0 down | Mar 30, 2023 | $2.39M |
| Sep 30, 2022 | -$2.80 | -$0.80 | N/A | -250.00% | Miss | N/A | N/A | N/A | Nov 10, 2022 | $2.21M |
| Jun 30, 2022 | -$1.80 | -$1.00 | N/A | -80.00% | Miss | N/A | N/A | 0 up, 0 down | Aug 11, 2022 | $2.36M |
| Mar 31, 2022 | -$4.00 | -$1.00 | N/A | -300.00% | Miss | N/A | N/A | 0 up, 0 down | May 11, 2022 | $2.45M |
| Dec 31, 2021 | -$0.09 | -$0.08 | -$0.08 - -$0.08 | -12.50% | Miss | N/A | 1 | 0 up, 0 down | Mar 30, 2022 | $2.44M |
| Sep 30, 2021 | -$1.60 | -$2.00 | N/A | +20.00% | Beat | N/A | N/A | 0 up, 0 down | Nov 12, 2021 | $2.25M |
| Jun 30, 2021 | -$2.80 | -$2.00 | N/A | -40.00% | Miss | N/A | N/A | N/A | Aug 12, 2021 | $2.34M |
| Mar 31, 2021 | -$1.60 | -$2.00 | -$2.00 - -$2.00 | +20.00% | Beat | N/A | 1 | N/A | May 14, 2021 | $1.82M |
| Dec 31, 2020 | -$0.11 | -$0.09 | N/A | -22.22% | Miss | N/A | N/A | N/A | Mar 29, 2021 | $1.94M |
| Sep 30, 2020 | -$4.20 | -$4.00 | N/A | -5.00% | Miss | N/A | N/A | N/A | Nov 13, 2020 | $4.10M |
| Jun 30, 2020 | -$4.00 | -$4.00 | -$4.00 - -$4.00 | 0.00% | In line | N/A | 1 | N/A | Aug 13, 2020 | $1.31M |
| Mar 31, 2020 | -$12.72 | -$3.60 | -$3.60 - -$3.60 | -253.33% | Miss | N/A | 1 | N/A | May 14, 2020 | $1.22M |
| Dec 31, 2019 | -$0.48 | -$0.17 | -$0.25 - -$0.10 | -182.35% | Miss | N/A | 2 | N/A | Mar 27, 2020 | $688000 |
| Sep 30, 2019 | -$6.20 | -$7.80 | -$7.80 - -$7.80 | +20.51% | Beat | N/A | 1 | N/A | Nov 13, 2019 | $784000 |
| Jun 30, 2019 | -$21.00 | -$7.40 | -$7.40 - -$7.40 | -183.78% | Miss | N/A | 1 | N/A | Aug 9, 2019 | $942000 |
| Mar 31, 2019 | -$0.48 | -$0.43 | N/A | -11.63% | Miss | N/A | N/A | N/A | Apr 16, 2019 | $713000 |
| Dec 31, 2018 | -$0.23 | -$0.67 | N/A | +65.67% | Beat | N/A | N/A | N/A | Feb 27, 2019 | $685000 |
| Sep 30, 2018 | -$0.17 | $0.57 | N/A | -129.82% | Miss | N/A | N/A | N/A | Nov 19, 2018 | $650000 |
| Jun 30, 2018 | -$0.15 | $1.93 | N/A | -107.77% | Miss | N/A | N/A | N/A | Aug 17, 2018 | $817000 |
| Mar 31, 2018 | -$0.47 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 13, 2018 | $712000 |
| Dec 31, 2017 | -$1.23 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 28, 2018 | $1.25M |
| Sep 30, 2017 | -$1.36 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 20, 2017 | $270000 |
| Jun 30, 2017 | -$15.35 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 21, 2017 | $260000 |
| Mar 31, 2017 | -$1.38 | N/A | N/A | N/A | N/A | -100.9% | N/A | N/A | Apr 13, 2017 | N/A |
| Dec 31, 2016 | -$31.50 | N/A | N/A | N/A | N/A | -8850.0% | N/A | N/A | Mar 15, 2017 | $618000 |
| Sep 30, 2016 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Nov 14, 2016 | $365000 |
| Jun 30, 2016 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Aug 12, 2016 | $504000 |
| Mar 31, 2016 | $162.00 | -$76.50 | N/A | +311.76% | Beat | N/A | N/A | N/A | Apr 14, 2016 | $236000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2024 was -$6.29, after -$8.70 in the fiscal year ended Dec 31, 2022. It was -$724.50 for the year ended Dec 31, 2013, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2024 | -$6.29 | N/A |
| Dec 31, 2022 | -$8.70 | N/A |
| Dec 31, 2021 | -$6.09 | N/A |
| Dec 31, 2020 | -$21.03 | N/A |
| Dec 31, 2019 | -$28.16 | N/A |
| Dec 31, 2018 | -$1.02 | N/A |
| Dec 31, 2017 | -$19.32 | -114.8% |
| Dec 31, 2016 | $130.50 | N/A |
| Dec 31, 2015 | -$1,115.64 | N/A |
| Dec 31, 2013 | -$724.50 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,100 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,106 | 8 | |
| 2026Q2 | Jun 30, 2026 | 2,940 | 3 | |
| 2026Q1 | Mar 31, 2026 | 4,141 | 4 | |
| 2025Q2 | Jun 30, 2025 | 2,390 | 2 | |
| 2025Q1 | Mar 31, 2025 | 3,175 | 2 | |
| 2024Q3 | Sep 30, 2024 | 1,741 | 2 | |
| 2024Q2 | Jun 30, 2024 | 1,878 | 2 |
2026Q3 Earnings Call
Opening remarks
Ilan Danieli CEO Good afternoon, everyone, and thank you for joining us. Before we jump into a review of the results for Q3 2026 and share several thoughts for 2027, I thought that as we come to the end of another successful year, it might be helpful to add another member of the management team to these calls. I'd like to introduce my co-founder and Precipio's Chief Operating Officer, Zaki Sabet. Along with Dr. Ayman Mohamed, the three of us started Precipio in 2011, and we've been inseparable since. Prior to founding Precipio, Zaki spent his career in the diagnostics industry. While at college, Zaki worked as an accessioner during the night shift in a lab in New Jersey. Over the years, he moved up through the ranks from lab technician to supervisor and eventually managed the entire laboratory. Bringing his in-depth expertise, Zaki was responsible for building what is today, to the best of our knowledge, at our size, one of the few profitable hematopathology laboratories in the country. At Precipio, Zaki oversees all company operations, including both our clinical laboratory and operations for the products division, including manufacturing and supply chain. Today, Zaki will be joining me in sharing some remarks, and then we'll also be available to answer questions during the Q&A section. As this is our last scheduled shareholder call of 2026, I'd like to put these results in the context of the progress we've made over the past couple of years and explain how that progress sets the stage for 2027. In 2025, our focus was on getting the company to a cash-flow-positive position. We'd gone through several dilutive financings and decided that it was time for the company to stand on its own two feet and become financially independent. So we set our sights on reaching cash flow positive through a combination of revenue growth alongside significant operational efficiency improvements. And at the end of 2025, we were there. Our company was cash flow positive, no longer dependent on outside capital in order to survive. And for the first time, we were able to respond to the calls from the various investment banks and hedge funds looking to provide capital to Precipio with a polite but clear, 'No, thank you.' I can tell you, as the person responsible for raising money to keep the lights on for 15 years, that was a wonderful moment. The second goal in 2025 was to determine if the products we created and that were used in our own lab would be of real value to other laboratories. We carefully explored this market by identifying target customers in several segments, which would serve as an indicator of market interest.
Frequently Asked Questions About PRPO
When is Precipio's next earnings date?
Precipio's next earnings report is expected for Mar 29, 2027.
How often does PRPO beat earnings estimates?
Precipio beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of -87.34%.
PRPO pages: Overview, Earnings, Financials, Valuation, Competitors